Genovis Stock

Genovis EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Genovis (GENO.ST) as of Aug 17, 2026 is 32.62. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 29.51 — a change of 10.54% (higher).

EV/FCF

32.62

YoY

10.54%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Genovis is 2026 32.62 . EV/FCF (Enterprise Value to Free Cash Flow) of Genovis was 2025 29.51 . It decreases by 10.54% higher compared to the previous year.
Access this data via the Eulerpool API

Genovis Stock analysis

What does Genovis do? Genovis AB is a Swedish company that offers biotechnology solutions for drug research and diagnostic industries. The company was founded in Lund, Sweden in 1999 and currently employs over 30 employees. Genovis began with the development of enzymes for protein-based therapeutics, but over time expanded its business to include enzymes for improved analysis methods in mass spectrometry. Genovis has become a leading provider of innovative enzyme solutions and proteomics tools for biomedical research. The company's business model is based on providing specially developed enzymes and proteomics tools to companies in drug research and diagnostic industries. Genovis has two main business areas: marketing enzymes and providing peptide synthesis services. The first business area is the marketing of enzymes for the separation of glycosylated proteins in mass spectrometry. The company develops and produces these enzymes for various applications such as Alzheimer's research, cancer research, and infectious diseases. Genovis is also an important provider of enzymes for the investigation of antibody-drug conjugates used in novel therapeutic approaches. The second business area is providing peptide synthesis services. The company also has a diversified biotechnology infrastructure and offers analysis and synthesis services for peptides in various fields, such as immunotherapy and diagnostics. Genovis' product portfolio includes a variety of enzymes that have broad application in drug research and diagnostic industries. This includes enzymes for antibody proteolysis, enzymes for the synthesis of glycoconjugates, and enzymes for conjugated protein analysis. In addition, the company also offers specialized kits for protein analysis. Genovis kits always include all necessary components such as proteases, buffer systems, and instructions to conduct the offered experiments. In conclusion, Genovis is a leading company in the biotechnology industry that offers innovative enzyme solutions and proteomics tools for a variety of applications in medical research and diagnostics. With its diversified biotechnology infrastructure and dedicated employees, the company can meet the growing needs of its customers in the science and industry sectors and has become a key partner in the healthcare industry. Genovis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genovis stock

EV/FCF (Enterprise Value to Free Cash Flow) of Genovis is 32.62 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Genovis changed from 29.51 to 32.62, representing a 10.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Genovis since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Genovis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Genovis

All Key Metrics — Genovis